MARKET

NGNE

NGNE

Neurogene
NASDAQ
20.60
-1.51
-6.83%
After Hours: 20.60 0 0.00% 17:19 12/31 EST
OPEN
22.22
PREV CLOSE
22.11
HIGH
22.99
LOW
20.35
VOLUME
157.86K
TURNOVER
--
52 WEEK HIGH
37.27
52 WEEK LOW
6.88
MARKET CAP
319.09M
P/E (TTM)
-5.0045
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NGNE last week (1222-1226)?
Weekly Report · 12/29/2025 09:01
Weekly Report: what happened at NGNE last week (1215-1219)?
Weekly Report · 12/22/2025 09:01
Short Report: Vera Therapeutics bears retreat as stock rallies
TipRanks · 12/21/2025 23:50
Tracking Baker Brothers Portfolio - Q3 2025 Update
Seeking Alpha · 12/16/2025 14:19
Weekly Report: what happened at NGNE last week (1208-1212)?
Weekly Report · 12/15/2025 09:02
Weekly Report: what happened at NGNE last week (1201-1205)?
Weekly Report · 12/08/2025 09:02
Neurogene Grants Stock Options to New Employees Under 2025 Inducement Plan
Reuters · 12/04/2025 21:01
NEUROGENE ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 12/04/2025 21:01
More
About NGNE
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.

Webull offers Neurogene Inc stock information, including NASDAQ: NGNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NGNE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NGNE stock methods without spending real money on the virtual paper trading platform.